<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Phase 1 testing of ezatiostat, a <z:chebi fb="0" ids="16856">glutathione</z:chebi> S-transferase P1-1 inhibitor, for the treatment of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> was conducted in a multidose-escalation study </plain></SENT>
<SENT sid="1" pm="."><plain>Patients received 10 dose levels (200, 400, 1000, 1400, 2000, 2400, 3000, 4000, 5000, and 6000 mg) of ezatiostat tablets in divided doses on days 1 to 7 of a 21-day cycle for a maximum of 8 cycles </plain></SENT>
<SENT sid="2" pm="."><plain>The safety and pharmacokinetics of ezatiostat were evaluated </plain></SENT>
<SENT sid="3" pm="."><plain>Forty-five patients with low to intermediate-2 International Prognostic Scoring System risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> were enrolled </plain></SENT>
<SENT sid="4" pm="."><plain>No dose-limiting toxicities were observed </plain></SENT>
<SENT sid="5" pm="."><plain>The most common grade 1 or 2, respectively, treatment-related adverse events were nonhematologic: <z:hpo ids='HP_0002018'>nausea</z:hpo> (56%, 9%), <z:hpo ids='HP_0002014'>diarrhea</z:hpo> (36%, 7%), <z:hpo ids='HP_0002013'>vomiting</z:hpo> (24%, 7%), <z:hpo ids='HP_0002027'>abdominal pain</z:hpo> (9%, 0%), <z:hpo ids='HP_0002019'>constipation</z:hpo> (4%, 9%), <z:hpo ids='HP_0002039'>anorexia</z:hpo> (3%, 7%), and <z:e sem="disease" ids="C0013395" disease_type="Disease or Syndrome" abbrv="">dyspepsia</z:e> (3%, 7%) </plain></SENT>
<SENT sid="6" pm="."><plain>Concentration of the primary active metabolite, TLK236, increased proportionate to ezatiostat dosage </plain></SENT>
<SENT sid="7" pm="."><plain>Seventeen hematologic improvement (HI) responses by International Working Group criteria were observed at dose levels of 200 to 6000 mg/day with 11 HI responses at doses of 4000 to 6000 mg/day </plain></SENT>
<SENT sid="8" pm="."><plain>HI responses occurred in <z:hpo ids='HP_0000001'>all</z:hpo> lineages including 3 bilineage and 1 complete cytogenetic response </plain></SENT>
<SENT sid="9" pm="."><plain>Decreased number of red blood cell and platelet transfusions and in some cases transfusion independence were attained </plain></SENT>
<SENT sid="10" pm="."><plain>Extended dose schedules of ezatiostat tablets are under investigation </plain></SENT>
</text></document>